M Olling

814 total citations
35 papers, 622 citations indexed

About

M Olling is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Health, Toxicology and Mutagenesis. According to data from OpenAlex, M Olling has authored 35 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 5 papers in Pediatrics, Perinatology and Child Health and 5 papers in Health, Toxicology and Mutagenesis. Recurrent topics in M Olling's work include Drug Solubulity and Delivery Systems (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Pesticide Residue Analysis and Safety (4 papers). M Olling is often cited by papers focused on Drug Solubulity and Delivery Systems (4 papers), Drug-Induced Hepatotoxicity and Protection (4 papers) and Pesticide Residue Analysis and Safety (4 papers). M Olling collaborates with scholars based in Netherlands, Guinea-Bissau and Canada. M Olling's co-authors include A.G. Rauws, D.M. Barends, A.P.J.M. de Jong, H.J.G.M. Derks, Vinod P. Shah, Gordon L. Amidon, H. Möller, Hans E. Junginger, Jan Welink and K.K. Midha and has published in prestigious journals such as Chemosphere, Analytica Chimica Acta and Aquaculture.

In The Last Decade

M Olling

34 papers receiving 572 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Olling Netherlands 15 161 124 104 99 77 35 622
Nageswara Rao Pilli India 17 53 0.3× 124 1.0× 292 2.8× 51 0.5× 57 0.7× 42 1.0k
Joel P. Bercu United States 20 43 0.3× 201 1.6× 58 0.6× 82 0.8× 54 0.7× 45 725
M. Lallier Belgium 8 51 0.3× 36 0.3× 366 3.5× 37 0.4× 27 0.4× 11 964
R.R. Brodie United States 15 39 0.2× 10 0.1× 135 1.3× 45 0.5× 76 1.0× 42 570
Lee T. Grady United States 11 55 0.3× 74 0.6× 63 0.6× 31 0.3× 19 0.2× 36 459
Susanne Glowienke Switzerland 16 37 0.2× 172 1.4× 55 0.5× 26 0.3× 41 0.5× 28 700
Zbyněk Svoboda Czechia 14 42 0.3× 20 0.2× 76 0.7× 17 0.2× 161 2.1× 27 580
C. Nivet France 4 36 0.2× 28 0.2× 210 2.0× 27 0.3× 16 0.2× 6 607
Ludmila Matysová Czechia 14 68 0.4× 28 0.2× 360 3.5× 27 0.3× 41 0.5× 31 888
Anabela Almeida Portugal 14 19 0.1× 53 0.4× 197 1.9× 124 1.3× 43 0.6× 38 1.1k

Countries citing papers authored by M Olling

Since Specialization
Citations

This map shows the geographic impact of M Olling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Olling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Olling more than expected).

Fields of papers citing papers by M Olling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Olling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Olling. The network helps show where M Olling may publish in the future.

Co-authorship network of co-authors of M Olling

This figure shows the co-authorship network connecting the top 25 collaborators of M Olling. A scholar is included among the top collaborators of M Olling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Olling. M Olling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Welink, Jan, Gordon L. Amidon, Hans E. Junginger, et al.. (2004). Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. Journal of Pharmaceutical Sciences. 93(8). 1945–1956. 139 indexed citations
2.
Olling, M, et al.. (1999). Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharmaceutics & Drug Disposition. 20(1). 19–28. 41 indexed citations
3.
Olling, M, et al.. (1999). In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics. 48(1). 13–19. 44 indexed citations
4.
Olling, M, et al.. (1999). Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharmaceutics & Drug Disposition. 20(1). 19–28. 6 indexed citations
5.
Aldenkamp, Albert P., J.A.R.J. Hulsman, Marian Majoie, et al.. (1998). Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates. European Journal of Clinical Pharmacology. 54(2). 185–192. 20 indexed citations
6.
Piersma, Aldert H., et al.. (1998). Embryotoxicity of carbamazepine in rat postimplantation embryo culture after in vitro exposure via three different routes. Reproductive Toxicology. 12(2). 161–168. 17 indexed citations
7.
Olling, M, et al.. (1997). The oral bioavailability of sodium nitrite investigated in healthy adult volunteers. Rivm Repository (Netherlands National Institute for Public Health and the Environment). 12 indexed citations
8.
Piersma, Aldert H., et al.. (1996). Teratogenicity of a Single Oral Dose of Retinyl Palmitate in the Rat, and the Role of Dietary Vitamin A Status. Pharmacology & Toxicology. 79(3). 131–135. 4 indexed citations
9.
Olling, M, et al.. (1995). Rabbit model for estimating relative bioavailability, residues and tissue tolerance of intramuscular products: comparison of two ampicillin products. Journal of Veterinary Pharmacology and Therapeutics. 18(1). 34–37. 9 indexed citations
10.
Tanck, Michael W.T., et al.. (1995). Negative effect of malachite green on haematocrit of rainbow trout (Onchorhynchus mykiss Walbaum). 3 indexed citations
11.
Olling, M, et al.. (1995). Congener-specific bioavailability of PCDD/Fs and coplanar PCBs in cows: Laboratory and field measurements. Chemosphere. 31(8). 3827–3838. 42 indexed citations
12.
Tanck, Michael W.T., et al.. (1995). Negative effect of malachite green on the haematocrit of rainbow trout (Oncorhynchus mykiss Walbaum).. Socio-Environmental Systems Modeling. 5(4). 134–136. 6 indexed citations
13.
Olling, M, et al.. (1994). The bioavailability of diclofenac from enteric coated products in healthy volunteers with normal and artificially decreased gastric acidity. Biopharmaceutics & Drug Disposition. 15(9). 775–788. 11 indexed citations
14.
Everts, Helen B., et al.. (1993). Een fysiologisch farmacokinetisch model voor 2,3,7,8-TCDD in de koe. 3 indexed citations
15.
Olling, M, et al.. (1990). Comparative antidotal efficacy of activated charcoal tablets, capsules and suspension in healthy volunteers. European Journal of Clinical Pharmacology. 39(5). 501–505. 15 indexed citations
16.
Olling, M, et al.. (1988). Farmacokinetiek van urethaan bij de rat. 1 indexed citations
17.
Olling, M & A.G. Rauws. (1986). Evaluation program BIOTEST applied to bioavailability tests of paracetamol preparations.. PubMed. 8(10). 629–31. 2 indexed citations
18.
Rauws, A.G., et al.. (1982). The Pharmacokinetics of Prunasin, a Metabolite of Amygdalin. Journal of Toxicology Clinical Toxicology. 19(8). 851–856. 22 indexed citations
19.
Olling, M, et al.. (1980). Interactions of aspirin with acetaminophen and caffeine in rat stomach: Pharmacokinetics of absorption and accumulation in gastric mucosa. Journal of Pharmaceutical Sciences. 69(8). 900–906. 14 indexed citations
20.
Rauws, A.G. & M Olling. (1976). Treatment of experimental imipramine and desipramine poisoning in the rat. Archives of Toxicology. 35(2). 97–106. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nageswara Rao Pilli Breakdown of academic impact, for papers by Joel P. Bercu Breakdown of academic impact, for papers by M. Lallier Breakdown of academic impact, for papers by R.R. Brodie Breakdown of academic impact, for papers by Lee T. Grady Breakdown of academic impact, for papers by Susanne Glowienke Breakdown of academic impact, for papers by Zbyněk Svoboda Breakdown of academic impact, for papers by C. Nivet Breakdown of academic impact, for papers by Ludmila Matysová Breakdown of academic impact, for papers by Anabela Almeida
Rankless by CCL
2026